(A) Unsupervised clustering of cytosine methylation profiles from seven primary patient-derived pancreatic cancer associated fibroblasts (CAFs) and four healthy controls (Hst: Hepatic stellate …
(A) A set of 120 transcripts are commonly hypomethylated in primary patient-derived CAFs and de novo generated CAFs and includes CXCR4. (B,C) The CXCR4 promoter is demethylated in primary …
(A) CXCR4 siRNAs lead to knockdown of protein in CAFs when compared to control siRNAs. Western blot and image intensity is shown. (B) CXCR4 knockdown in dn-CAFs leads to abrogation of the increased …
(A) Mapping of carbon atoms transition using U-13C3-lactate. Mass isotopomer distribution (MID) shows uptake of labelled lactate by MSCs cultured in α-MEM leading to the generation of α-KG (M2 αKG) …
(A) Mass Isotopologue Distribution of Alanine from U-13C-Lactate tracing experiments indicate that lactate-derived carbon contributes significantly to de novo alanine synthesis. These experiments …
(A) Conditioned media from ctrl and LDH siRNA mediated knockdown PANC-1 (PDAC) cells was collected. MSCs were exposed to control conditioned media (ctrl), or LDH knockdown conditioned and used to …
(A) Genome wide 5hmC analysis was done by OXBS in MSCs and converted CAFs. 5hmC gains are depicted as percentage gained (CAF/MSC) and were seen to occur throughout the genome (B) 5hmC gains in CAFs …
(A, B) 5hmC (A) and CXCR4 (B) immunohistochemical staining was done on human PDAC TMAs and grading of intensity of stain in the tumor stromal CAFs was estimated. (C) Most CAF like cells in PDAC …
(A) Wildtype and TET2 KO MSCs were exposed to conditioned media from KPC PDAC cells for 14 days. TET2 KO MSCs demonstrated decreased fibroblastic appearance when compared to wildtype controls. (B,C) …
Rank | Name | P-value | q-value (Benjamini) | # Target Sequences with Motif | % of Targets Sequences with Motif | # Background Sequences with Motif | % of Background Sequences with Motif | Motif |
---|---|---|---|---|---|---|---|---|
1 | Atf3(bZIP)/GBM-ATF3-ChIP-Seq(GSE33912)/Homer | 1.00E-07 | 0 | 344 | 7.86% | 2593.1 | 5.81% | ![]() |
2 | AP-1(bZIP)/ThioMac-PU.1-ChIP-Seq(GSE21512)/Homer | 1.00E-06 | 0 | 383 | 8.75% | 2995.7 | 6.71% | ![]() |
3 | Jun-AP1(bZIP)/K562-cJun-ChIP-Seq(GSE31477)/Homer | 1.00E-05 | 0.0003 | 112 | 2.56% | 722.1 | 1.62% | ![]() |
4 | BMAL1(bHLH)/Liver-Bmal1-ChIP-Seq(GSE39860)/Homer | 1.00E-05 | 0.0003 | 857 | 19.57% | 7567 | 16.95% | ![]() |
5 | Fosl2(bZIP)/3T3L1-Fosl2-ChIP-Seq(GSE56872)/Homer | 1.00E-05 | 0.0003 | 149 | 3.40% | 1040.8 | 2.33% | ![]() |
6 | BATF(bZIP)/Th17-BATF-ChIP-Seq(GSE39756)/Homer | 1.00E-05 | 0.0003 | 322 | 7.35% | 2570.8 | 5.76% | ![]() |
7 | Fra1(bZIP)/BT549-Fra1-ChIP-Seq(GSE46166)/Homer | 1.00E-04 | 0.0006 | 266 | 6.07% | 2089.9 | 4.68% | ![]() |
8 | Smad2(MAD)/ES-SMAD2-ChIP-Seq(GSE29422)/Homer | 1.00E-04 | 0.0011 | 652 | 14.89% | 5725.2 | 12.83% | ![]() |
9 | NPAS2(bHLH)/Liver-NPAS2-ChIP-Seq(GSE39860)/Homer | 1.00E-04 | 0.0026 | 543 | 12.40% | 4734.1 | 10.61% | ![]() |
10 | Smad4(MAD)/ESC-SMAD4-ChIP-Seq(GSE29422)/Homer | 1.00E-03 | 0.003 | 655 | 14.96% | 5819.3 | 13.04% | ![]() |
11 | Smad3(MAD)/NPC-Smad3-ChIP-Seq(GSE36673)/Homer | 1.00E-03 | 0.0035 | 1238 | 28.27% | 11533 | 25.84% | ![]() |
12 | Usf2(bHLH)/C2C12-Usf2-ChIP-Seq(GSE36030)/Homer | 1.00E-03 | 0.0042 | 200 | 4.57% | 1574.5 | 3.53% | ![]() |
13 | HIF2a(bHLH)/785_O-HIF2a-ChIP-Seq(GSE34871)/Homer | 1.00E-03 | 0.0066 | 178 | 4.06% | 1393.5 | 3.12% | ![]() |
14 | CEBP:CEBP(bZIP)/MEF-Chop-ChIP-Seq(GSE35681)/Homer | 1.00E-03 | 0.0141 | 107 | 2.44% | 789.3 | 1.77% | ![]() |
15 | MafA(bZIP)/Islet-MafA-ChIP-Seq(GSE30298)/Homer | 1.00E-02 | 0.023 | 315 | 7.19% | 2709.1 | 6.07% | ![]() |
16 | Bach2(bZIP)/OCILy7-Bach2-ChIP-Seq(GSE44420)/Homer | 1.00E-02 | 0.023 | 86 | 1.96% | 622.7 | 1.40% | ![]() |
17 | Brachyury(T-box)/Mesoendoderm-Brachyury-ChIP-exo(GSE54963)/Homer | 1.00E-02 | 0.0326 | 134 | 3.06% | 1056.7 | 2.37% | ![]() |
18 | USF1(bHLH)/GM12878-Usf1-ChIP-Seq(GSE32465)/Homer | 1.00E-02 | 0.0387 | 190 | 4.34% | 1574.4 | 3.53% | ![]() |
19 | n-Myc(bHLH)/mES-nMyc-ChIP-Seq(GSE11431)/Homer | 1.00E-02 | 0.0511 | 272 | 6.21% | 2354.1 | 5.27% | ![]() |
20 | Fli1(ETS)/CD8-FLI-ChIP-Seq(GSE20898)/Homer | 1.00E-02 | 0.0528 | 439 | 10.03% | 3953.7 | 8.86% | ![]() |
Pathways that are overexpressed and demethylated in pancreatic cancer associated fibroblasts.
Common sets of genes epigenetically altered in primary and de novo generated CAFs.
Differentially expressed transcripts after CXCR knockdown in CAF cells.